Related Experiment Video
Updated: Dec 18, 2025
05:46
Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
Published on: May 27, 2022
6.7K
Differentiating Full-Spectrum Hemp Extracts from CBD Isolates: Implications for Policy, Safety and Science
Osvaldo Marinotti1, Miles Sarill1
1Science, Regulation & Education, CV Sciences, Inc, San Diego, CA, USA.
Journal of Dietary Supplements
|June 17, 2020
Summary
The 2018 Farm Bill legalized hemp, boosting hemp-derived cannabidiol (CBD) popularity. This study clarifies the differences between full-spectrum hemp extracts and CBD isolates, aiding consumer understanding and regulatory clarity.
Area of Science:
- Agricultural Science
- Pharmacology
- Regulatory Science
Background:
- The 2018 Agriculture Improvement Act reclassified industrial hemp (<0.3% THC) as an agricultural commodity, removing it from the Controlled Substances Act.
- Consumer interest in hemp-derived cannabidiol (CBD) supplements has surged, outpacing scientific understanding of their benefits, safety, and composition.
- The Food and Drug Administration (FDA) recognizes CBD as a drug (Epidiolex) for specific epilepsy treatments, creating regulatory complexity for supplements.
Purpose of the Study:
- To differentiate botanical full-spectrum hemp extracts containing CBD from isolated CBD preparations.
- To provide clarity from phytochemical, toxicological, and regulatory perspectives.
- To address the gap between consumer popularity and scientific understanding of hemp-derived CBD supplements.
Main Methods:
- Phytochemical analysis of hemp extracts.
- Toxicological assessment of CBD products.
- Review of regulatory frameworks for hemp-derived products.
Main Results:
- Full-spectrum hemp extracts contain a complex matrix of phytochemicals, distinct from isolated CBD.
- Variability in composition and potential contaminants exist in hemp-derived CBD supplements.
- Regulatory landscape for CBD products remains complex due to dual classification as a supplement and an approved drug.
Conclusions:
- Distinguishing between full-spectrum hemp extracts and CBD isolates is crucial for accurate assessment and regulation.
- Further research is needed to fully understand the safety, efficacy, and composition of hemp-derived CBD supplements.
- Clearer regulatory guidelines are necessary to ensure consumer safety and product integrity in the burgeoning CBD market.
Related Concept Videos
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
94
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
94
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
95
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
95
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
99
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
99
01:26Pharmaceutical Equivalents
129
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
129
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
116
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
116
01:28Drug Products: Biologics, Biosimilars and Interchangeables
165
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
165